Introduction
Anogenital warts are increasing in incidence and conventional management with chemical and physical ablative therapy is often associated with unsatisfactory response rates and a high incidence of recurrent disease.'-' Ablative therapy aims to remove clinically visible condylomata but latent human papillomavirus (HPV) infection in adjacent apparently normal epithelium may remain and be responsible for the high recurrence rates. 4 Inclusion of a wider margin of apparently normal epithelium around lesions undergoing ablative treatment is recommended as one means of attempting to address this problem but in addition and perhaps more theoretically attractive is the use of a systemically administered agent which may act at all such sites of infection. The known antiviral, antiproliferative and immunomodulatory properties of interferons (IFNs) make such agents attractive adjuvant treatment to be used in conjunction with standard "debulking" ablative therapies. IFN treatment, however, is associated with characteristic adverse effects, involves significant expense and may necessitate more visits to the clinic to administer. It is important therefore that clear and significant clinical benefit be demonstrated if such agents are to be prescribed. This study was designed to test the hypothesis that the combination of subcutaneous IEN alpha-2a at a dose of 3 MIU three times weekly for 10 weeks and physical ablative treatment would produce a 30% or more improvement in lasting response rates at week 38 in patients with external genital and/or perianal warts when compared with ablative therapy and placebo. The A baseline assessment was performed immediately prior to the first injection and ablative treatment on day 1 to include a description of location, type and number of lesions and estimated operability.
An assessment of disease state was carried out at the end of weeks 4, 6 and 10. Any adverse events, intercurrent illnesses or changes in concomitant medication were noted. The number and type of ablative treatments was recorded at the end of week 6. Patients with a partial response only at week 10 assessment were withdrawn. Patients with a complete response at week 10 were seen every four weeks during the 28 weeks of follow-up or until there was recurrence. Patients noting a recurrence between week 10 and week 38 were asked to return to the trial centre immediately where the next monthly assessment was performed. They were subsequently withdrawn and treatment was at the discretion of the supervising physician.
Laboratory investigations Blood was taken for haemoglobin concentration, white blood cell count, platelet count, creatinine and AST during the pre-study screen, at weeks 0, 4, 10 and 14. In the event of unexplained or unexpected test value abnormalities, the tests were repeated immediately and followed up until the results returned to the normal range and/or an adequate explanation of the abnormality was found. Demographic data and pre-study characteristics There were no significant differences between treatment groups in age, weight, height, sex distribution, race, sexual orientation or smoking habit. The groups were comparable for previous treatments for their anogenital warts and for concomitant diseases and medication. Table 1 summarises pretreatment lesion characteristics which showed no notable differences between treatment groups. The majority of internal warts involved the vagina in all treatment groups with smaller numbers affecting the cervix, anal canal, urethral meatus and urethra.
Histopathology and HPV typing data Tables 2 and 3 outline the microscopic morphology and HPV DNA types detected respectively in biopsy specimens taken. The predominant microscopic morphology was The most frequently reported adverse events in the IFN-treated patients were headaches, fatigue, flu-like symptoms, local erythema, dizziness and myalgia. The most common adverse events in placebo-treated patients were headache, fatigue, dizziness, nasal congestion and flu-like symptoms. The majority of adverse events were of mild severity and most were considered by the investigator to be probably or possibly related to the study drug.
Laboratory data All HIV antibody tests were negative. There were no clinically relevant changes in median haemoglobin, creatinine or AST levels during the study. Median leucocyte count fell in both ment levels by week 14. Median platelet levels declined slightly in both IFN-treated groups at week 4. In the 1 MIU IFN group the platelet count remained at this lower level at week 14 (270.5 x 103/L compared with a pretreatment level of 283 x 103/1) but in the 3 MIU group returned to near pretreatment levels. Discussion HPV infection of the anogenital epithelium is a multicentric process and in addition to the production of clinically visible condylomata acuminata may produce latent and clinically inapparent "disease". It 
